300294.SZ
博雅生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.43
−4.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 2.1B | 1.7B | 2.7B | 2.8B |
| Cost of Revenue | 956.7M | 1.0B | 613.2M | 1.3B | 1.3B |
| Gross Profit | 887.6M | 1.0B | 1.1B | 1.4B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 48.2M | 54.6M | 66.9M | 67.7M | 49.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 239.9M | 239.2M | 186.7M | 194.9M | 230.0M |
| Selling & Marketing Expense | 386.5M | 412.7M | 419.6M | 582.6M | 695.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 668.5M | 707.1M | 666.1M | 834.7M | 971.6M |
| Cost and Expenses | 1.6B | 1.7B | 1.3B | 2.1B | 2.2B |
| Operating Income (EBIT) | (15.9M) | 109.4M | 477.3M | 355.2M | 532.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (23.5M) | 103.9M | 477.7M | 353.7M | 532.0M |
| Income Tax Expense | (26.9M) | (8.8M) | 81.2M | 105.6M | 86.5M |
| Bottom Line | |||||
| Net Income | 3.4M | 112.7M | 397.0M | 237.5M | 432.2M |
| Earnings from Cont. Ops | 3.4M | 112.6M | 396.5M | 215.1M | 376.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.4M | 112.7M | 397.0M | 237.5M | 432.2M |
| Per Share | |||||
| Basic EPS | CN¥0.02 | CN¥0.22 | CN¥0.79 | CN¥0.47 | CN¥0.86 |
| Diluted EPS | CN¥0.02 | CN¥0.22 | CN¥0.79 | CN¥0.47 | CN¥0.86 |
| Revenue Per Share | CN¥3.66 | CN¥4.02 | CN¥3.45 | CN¥5.25 | CN¥5.49 |
| Shares | |||||
| Basic Shares Outstanding | 503.7M | 512.3M | 502.5M | 505.2M | 502.6M |
| Diluted Shares Outstanding | 503.7M | 512.3M | 502.5M | 505.2M | 502.6M |
| Profitability Metrics | |||||
| EBITDA | — | 269.0M | 591.1M | 465.6M | 639.1M |
| D&A | — | 159.6M | 113.8M | 110.4M | 107.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026